Catalyst Biosciences, Inc. (CBIO)

NASDAQ: CBIO · IEX Real-Time Price · USD
0.290
-0.002 (-0.51%)
Feb 6, 2023, 2:05 PM EST - Market open
-0.51%
Market Cap 10.95M
Revenue (ttm) 3.23M
Net Income (ttm) 11.88M
Shares Out 37.76M
EPS (ttm) 0.38
PE Ratio 0.73
Forward PE n/a
Dividend $1.43 (493.10%)
Ex-Dividend Date Sep 21, 2022
Volume 949,083
Open 0.308
Previous Close 0.292
Day's Range 0.272 - 0.310
52-Week Range 0.092 - 0.650
Beta 1.38
Analysts Buy
Price Target 16.32 (+5,527.59%)
Earnings Date Mar 29, 2023

About CBIO

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The compan... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 45
Stock Exchange NASDAQ
Ticker Symbol CBIO
Full Company Profile

Financial Performance

In 2021, CBIO's revenue was $7.34 million, a decrease of -64.97% compared to the previous year's $20.95 million. Losses were -$87.93 million, 56.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for CBIO stock is "Buy." The 12-month stock price forecast is $16.32, which is an increase of 5,527.59% from the latest price.

Price Target
$16.32
(5,527.59% upside)
Analyst Consensus: Buy
Stock Forecasts

News

STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Catalyst Biosciences, Inc. - CBIO

NEW YORK , Jan. 4, 2023 /PRNewswire/ --  Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm ra...

1 month ago - PRNewsWire

SHAREHOLDER ALERT: Weiss Law Investigates Catalyst Biosciences, Inc.

NEW YORK , Jan. 4, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Catalyst Biosciences, Inc. ("Catalyst" o...

1 month ago - PRNewsWire

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Catalyst Biosciences, Inc. Merger

Wilmington, Delaware--(Newsfile Corp. - December 29, 2022) - Rigrodsky Law, P.A. is investigating Catalyst Biosciences, Inc. ("Catalyst") (NASDAQ CM: CBIO) regarding possible breaches of fiduciary dut...

1 month ago - Newsfile Corp

CBIO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Catalyst Biosciences, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Catalyst Biosciences, Inc. (NASDAQ: CBIO) and GNI Group Ltd. is fair to Catalyst shar...

1 month ago - Business Wire

Catalyst Biosciences Completes First Steps in Reverse Merger Plan

Acquires F351, a Phase 3 Drug to Treat Fibrosis

1 month ago - GlobeNewsWire

Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the ex-dividend date for the special,...

5 months ago - GlobeNewsWire

Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share

SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the Board of Directors has declared a ...

5 months ago - GlobeNewsWire

Catalyst Biosciences, Inc. Announces Dismissal of JDS1 Litigation

Company to Announce a Record Date for Initial Distribution in Due Course Company to Announce a Record Date for Initial Distribution in Due Course

6 months ago - GlobeNewsWire

Catalyst Biosciences Reports Second Quarter 2022 Operating & Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced its operating and financial results for the second quar...

6 months ago - GlobeNewsWire

JDS1, LLC Terminates Proxy Contest at Catalyst's 2022 Annual Meeting

FORT LEE, N.J.--(BUSINESS WIRE)--JDS1, LLC (“JDS1”), which collectively with the other reporting persons in its Section 13(d) group, beneficially owns approximately 8.4% of the outstanding common stoc...

6 months ago - Business Wire

Catalyst Biosciences Announces Withdrawal of JDS1 Nominations to the Board

Encourages Stockholders to Vote on the WHITE Proxy Card Encourages Stockholders to Vote on the WHITE Proxy Card

6 months ago - GlobeNewsWire

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Catalyst Stockholders Vote “FOR” All of the Company's Nominees on the WHITE Proxy Card

ISS and Glass Lewis Highlight That Stockholders Are Best Served by Allowing the Incumbent Board to Pursue Its Cash Distribution Plan  Catalyst Urges Stockholders to VOTE “FOR” All of the Company's Nom...

6 months ago - GlobeNewsWire

Catalyst Biosciences Publishes New Investor Presentation

Provides Details on Current Board's Cash Distribution Plan and Efforts to Maximize the Amount of Cash Available for Distribution

6 months ago - GlobeNewsWire

Catalyst Biosciences Announces Support from Largest Single Stockholder

JEC Capital Partners Agrees to Vote Its Shares in Favor of Catalyst's Nominees at the Company's 2022 Annual Meeting

6 months ago - GlobeNewsWire

JDS1, LLC Files Definitive Proxy Statement and Sends Letter to Catalyst Stockholders

FORT LEE, N.J.--(BUSINESS WIRE)--JDS1, LLC, which collectively with the other participants in its solicitation beneficially owns approximately 8.4% of the outstanding common stock of Catalyst Bioscien...

7 months ago - Business Wire

Catalyst Biosciences Sends Letter to Stockholders

Reiterates the Board's Commitment to Expeditiously Distributing All of the Company's Available Cash to Stockholders, Net of Liabilities and Obligations

7 months ago - GlobeNewsWire

Catalyst Biosciences Comments on Favorable Delaware Court of Chancery Ruling

Court Denies JDS1's Motion for Expedited Proceedings

7 months ago - GlobeNewsWire

Catalyst Biosciences Announces Plan to Distribute Cash to Stockholders

Board is Committed to Maximizing the Amount of Cash the Company Distributes to Stockholders

7 months ago - GlobeNewsWire

Has Catalyst Biosciences (CBIO) Outpaced Other Medical Stocks This Year?

Here is how Catalyst Biosciences, Inc. (CBIO) and Humana (HUM) have performed compared to their sector so far this year.

7 months ago - Zacks Investment Research

Why Is Catalyst Biosciences (CBIO) Stock Soaring 170% Today?

Catalyst Biosciences (CBIO) stock is rocketing higher on Monday after announcing the sale of its protease medicines portfolio. The post Why Is Catalyst Biosciences (CBIO) Stock Soaring 170% Today?

9 months ago - InvestorPlace

Why Catalyst Biosciences Shares Are Skyrocketing Today

Catalyst Biosciences Inc (NASDAQ: CBIO) shares are trading higher by 180.26% at $1.06 after the company announced it sold its complement portfolio for $60 million. A definitive asset purchase and sale...

9 months ago - Benzinga

Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex

Catalyst Biosciences Inc (NASDAQ: CBIO) has agreed to sell its portfolio of protease medicines that regulate complement to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) for $60 million. "This sal...

9 months ago - Benzinga

Catalyst Biosciences Sells Complement Portfolio for $60 Million

SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it has signed a definitive asset purchase and sale agreement with Vertex Ph...

9 months ago - GlobeNewsWire

Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results

SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2022.

9 months ago - GlobeNewsWire

Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update

SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth quarter and year ended Dece...

11 months ago - GlobeNewsWire